News
CMPS
13.58
+7.95%
1.00
Compass Pathways price target raised to $20 from $18 at Canaccord
TipRanks · 1h ago
COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright
TipRanks · 1d ago
3 Companies Redefining Healthcare Innovation
Seeking Alpha · 1d ago
COMPASS Pathways PLC put volume heavy and directionally bearish
TipRanks · 1d ago
Weekly Report: what happened at CMPS last week (0615-0619)?
Weekly Report · 4d ago
Unusually active option classes on open June 16th
TipRanks · 06/16 13:40
COMP360’s Phase 3 Success and FDA Filing Could Be A Game Changer For COMPASS Pathways (CMPS)
Simply Wall St · 06/15 19:12
Weekly Report: what happened at CMPS last week (0608-0612)?
Weekly Report · 06/15 09:15
Compass Pathways (CMPS) Stock After Phase 3 Success And Rolling FDA Filing How Does The Valuation Stack Up
Simply Wall St · 06/12 14:40
Weekly Report: what happened at CMPS last week (0601-0605)?
Weekly Report · 06/08 09:14
Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy
PUBT · 06/05 13:21
BRIEF-Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 06/05 10:33
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 06/05 05:30
Assessing COMPASS Pathways (CMPS) Valuation After Positive Phase 3 COMP360 Trial Milestone
Simply Wall St · 06/04 21:30
Hypha Labs flags cannabis-like growth pattern emerging in psychedelic industry
PUBT · 06/04 12:00
COMPASS Pathways Reaffirmed at Buy as Analyst Highlights Late-Stage Data, Commercial Readiness and Keeps $23 Price Target Unchanged
TipRanks · 06/02 11:36
Is COMPASS Pathways (CMPS) Recasting Its Commercialization Strategy With Kathleen Tregoning’s Board Appointment?
Simply Wall St · 06/01 09:23
Weekly Report: what happened at CMPS last week (0525-0529)?
Weekly Report · 06/01 09:15
Compass Pathways files Form 3 initial beneficial ownership statement for director Kathleen Tregoning
PUBT · 05/29 21:09
COMPASS Pathways PLC call volume above normal and directionally bullish
TipRanks · 05/29 18:31
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.